Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

This randomized phase IIB trial studies how well tamoxifen or afimoxifene works in treating patients with estrogen receptor positive breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate or afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.


Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate


Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive


Seema Khan, MD, Seema A. Khan, MD, Melissa L. Pilewskie, MD, Joseph M. Guenther, MD, Stephen R. Grobmyer, MD, Eun-Sil (Shelley) Hwang, MD, Amy C. Degnim, MD

See list of participating sites